News

Amicus Therapeutics to Engage Investors Through Key Conferences

Amicus Therapeutics to Engage Investors Through Key Conferences

Amicus Therapeutics to Engage Investors Through Key Conferences

Amicus Therapeutics has exciting plans to connect with investors through a series of important presentations scheduled for November. This initiative reflects the company’s dedication not only to advancing healthcare solutions for rare diseases but also to supporting its investor community.

Upcoming Investor Conferences

The company will be participating in the prestigious 2025 UBS Global Healthcare Conference, taking place in Palm Beach Gardens. This event is a key opportunity for Amicus Therapeutics to engage with investors, making a presentation on November 10.

What to Expect at UBS Conference

Management will kick off their presentation at 2:45 p.m. ET, providing insights into their innovative strategies and ongoing projects. This is a must-attend event for those interested in the future direction of the company.

Jefferies Global Healthcare Conference

Shortly after the UBS event, Amicus Therapeutics will take part in the Jefferies Global Healthcare Conference. This event, set for November 18, brings together key players in the healthcare sector from around the world.

Details for Jefferies Conference

Scheduled to begin at 4:30 p.m. GMT, this presentation represents another chance for the company to articulate its vision and present updates on its dynamic drug development pipeline.

Engaging Audiences Through Webcasts

For those unable to attend these conferences in person, Amicus will provide live audio webcasts, ensuring that a wider audience can gain insights into the company's progress. Interested individuals can access these presentations through the investor section of the Amicus Therapeutics corporate website.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is committed to being a leader in the biotechnology industry, developing innovative solutions for individuals with rare diseases. With a patient-centric focus, the company strives to enhance its portfolio with groundbreaking treatments that have the potential to change the lives of those affected by challenging conditions.

Company Objectives

The core mission of Amicus is to advance and expand its offerings, continuously pushing the boundaries of science to develop first- or best-in-class medicines. The company’s established reputation for prioritizing patient needs drives its ongoing research and development efforts.

Contact Information

For further inquiries or detailed information, investors can reach out to:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Brendan McEvoy
Executive Director, External Communications
bmcevoy@amicusrx.com
(609) 662-5005

Frequently Asked Questions

What is the focus of Amicus Therapeutics?

Amicus Therapeutics specializes in developing novel high-quality medicines aimed at treating rare diseases.

When will Amicus Therapeutics present at conferences?

Amicus will present on November 10 at the UBS Global Healthcare Conference and on November 18 at the Jefferies Global Healthcare Conference.

How can investors access the presentations?

Investors can access the live audio webcasts through the investor section of the Amicus Therapeutics corporate website.

Who can be contacted for investor relations?

Andrew Faughnan, Vice President of Investor Relations at Amicus, is the main contact for investor inquiries.

What type of company is Amicus Therapeutics?

Amicus Therapeutics is a biotechnology company focused on delivering innovative treatments for individuals affected by rare diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Helio Fred Garcia Honored by Diversity Action Alliance

Updated Category News Views 4

Award Ceremony Set in the Big Apple In an industry where recognition often feels as transient as a ticker's daily high, the Diversity Action Alliance (DAA) is doing its bit to emphasize the lasting impact individuals can make. On September 16 in New York City, Helio Fred Garcia will be honored with the 2026 Pat Ford Larger Than Life Impact Award at the DAA's Annual...

Continue Reading
Step Inside Henson's Creature Shop Magic in NYC

Updated Category News Views 2

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Continue Reading
K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Updated Category News Views 7

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

Continue Reading
Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Updated Category News Views 5

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Continue Reading
Albertsons Welcomes Once Upon a Coconut Nationwide

Updated Category News Views 4

Coconut Water Takes Over Grocery Aisles You know, for all the cautious optimism I wield, this here is a move that shows real muscle in the world of coconut water—I mean, slamming into Albertsons' grocery empire is no small potatoes! Once Upon a Coconut has landed its premium hydration cans across all the banners under this giant retailer. From that good ol' familiar...

Continue Reading
XKL Delivers MediaLight for High-Speed Optical Transport

Updated Category News Views 2

Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...

Continue Reading
Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Updated Category News Views 4

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Continue Reading
Atli Launches: AI-Powered eSIM Revolutionizes Travel

Updated Category News Views 5

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 3

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
Navigating Land Access: The Hidden Roadblock in Mining

Updated Category News Views 3

Mining's Often Overlooked Obstacle: Land Access In the world of mining, the shallow thrills of striking gold are often overshadowed by the frustrating slog of securing land access. You can have your permits lined up, your finances sorted, and drills humming along, but if you haven’t sweet-talked the folks farming above your visible vein of riches, you could be staring...

Continue Reading

Top 5 Most Recently Viewed Articles

Authenticom Group's Momentum: A Deep Dive into Their Success

Updated Category News Views 111

Authenticom Group's Revenue Growth Journey The Authenticom Group of Companies has recently celebrated an impressive achievement: its sixth consecutive month of record revenue. This notable success is attributed to the growing demand for their innovative data connectivity and customer experience solutions within the automotive sector. As the company strategically positions...

Continue Reading
Adagene Doses First Patient in Phase 2 Colorectal Cancer Trial

Updated Category News Views 147

Adagene Commences Phase 2 Trial with First Patient Dosed Adagene Inc., a pioneering biotechnology company focused on innovative antibody-based therapies, has taken a significant step forward in its latest clinical trial. The company recently announced the dosing of the first patient in their Phase 2 study of muzastotug, an advanced anti-CTLA-4 agent, in combination with...

Continue Reading
PharmaCorp Rx Inc. Announces Strategic Funding Prospectus Launch

Updated Category News Views 163

PharmaCorp Rx Inc. Files Final Short Form Base Shelf Prospectus The dynamic journey of PharmaCorp Rx Inc. (TSXV:PCRX) continues with the recent announcement of its Final Short Form Base Shelf Prospectus. This important step aligns with the company's vision for growth and development in the Canadian pharmacy landscape. Key Aspects of the Prospectus The newly filed...

Continue Reading
Sana Biotechnology Schedules September Investor Presentations

Updated Category News Views 279

Upcoming Investor Conferences for Sana Biotechnology Sana Biotechnology, Inc. (NASDAQ: SANA), a pioneering company dedicated to transforming patient care through engineered cells, has announced its plans to participate in several significant investor conferences in September. These events will showcase the company's vision and recent advancements in cell therapy, offering...

Continue Reading
Magic Software and Matrix I.T Explore Merger Opportunities

Updated Category News Views 394

Magic Software and Matrix I.T Discuss Merger Strategy Magic Software Enterprises Ltd. (NASDAQ: MGIC), a prominent player in IT consulting and software solutions, is embarking on a significant journey with a potential merger with Matrix I.T Ltd. (TASE: MTRX). This memorandum of understanding (MOU) is expected to redefine the technology landscape, facilitating expansive...

Continue Reading